Arcturus Therapeutics

Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

/wp-content/themes/rewalk-parent/default_media/arcturus_space_1mbit_vbr2.mp4
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
February 22, 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
READ MORE
March 1, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
READ MORE
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
May 3, 2021
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
READ MORE
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
READ MORE
June 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 26, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
READ MORE
July 28, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
READ MORE
August 2, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
August 3, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
READ MORE
August 9, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
READ MORE
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
September 8, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
READ MORE
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
READ MORE
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF_230.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_external_thumbnail.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF_230.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1634943445
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg?time=1634943445

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.